Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
Date:10/1/2009

ST. LOUIS, Oct. 1 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce the appointment of George Miller as Sr. Vice President, General Counsel and Secretary. In his new role, Miller will join the company's executive management team and manage its legal services and corporate governance processes. He will report to Jai Nagarkatti, Chairman, President & CEO.

Miller brings to Sigma-Aldrich twenty years of corporate legal experience from large global public companies in the chemical and transportation industries. Prior to his appointment at Sigma-Aldrich, Miller (age 54) was employed by Novartis, most recently as General Counsel in their New York office and previously in their offices in Basel, Switzerland and Tokyo, Japan. Prior to his employment with Novartis, Miller served as Managing Director-Regional Counsel for Federal Express Corporation in their Tokyo, Japan office. Miller earned his Juris Doctorate from Georgetown University Law Center in Washington DC, his Masters of International Management from Thunderbird's Garvin School of International Management, Glendale Arizona, and his Bachelor of Arts from the University of St. Thomas in St. Paul, Minnesota.

Chairman, President and CEO Jai Nagarkatti commented, "We are very pleased to be able to add such a talented professional as George to our organization. In addition to his many years of experience with other global companies, he also has extensive background in enterprise risk management, M&A, board governance, government relations, tax, patent & trademark infringement and litigation. His successful public company General Counsel experience will enhance our overall corporate governance practices and help us better manage legal services in our growing global businesses."

About Sigma-Aldrich: Sigma-Aldrich is a lead
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
3. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
4. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) First Quarter 2008 Financial Results Call Set for May 6
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Restoring a natural root signal helps to fight a major corn pest 9462 1Restoring a natural root signal helps to fight a major corn pest 9462 2Restoring a natural root signal helps to fight a major corn pest 9462 3Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 1Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 2Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 3Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 4Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 1Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 2Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 3Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 4Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 5Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 6Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 7
Other Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 2New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 3New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 4New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 5New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 6New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 7New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 8